Document Detail


Genome-scale analysis of lung cancer progression.
MedLine Citation:
PMID:  15174898     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Among cancers, lung cancer is the single biggest killer in the US. It is estimated that lung cancer was responsible for 171900 newly diagnosed cases of cancer in the US in 2003, and for 157200 deaths. Over many years, however, there has been little improvement in the clinical outcome of lung cancer, and any improvement in the incidence or mortality from lung cancer can largely be attributed to smoking cessation and not to the success of therapy. The histopathology of lung cancer reveals that it is a disease with many faces. Lung cancer is often nonresponsive to traditional therapy, leaving few, if any, alternatives in the management of the advanced stages of the disease. The molecular pathogenesis of lung cancer, only recently illuminated, involves numerous molecular and cell biological changes revealing a very complex disease progression. Large-scale mRNA expression analysis has been recently used to classify lung cancers molecularly. These techniques have been used successfully to differentiate lung cancer histotypes based on patterns of genes expressed. The use of protein analysis to this end has also been attempted, with limited correlation with RNA experiments. This likely reflects the limited sensitivity of the technologies and complex, poorly understood post-synthesis protein modifications. In any event, there have been great strides made in understanding the nature of lung cancer from a molecular perspective; these effects represent a great advancement in the diagnosis and prognosis of lung cancer. Moreover, these advances may lead to the improvement of patient survival by guiding the choice of more efficacious therapy.
Authors:
Uriel M Malyankar; John R MacDougall
Related Documents :
19828008 - Use of lung cancer risk models in planning research and service programs in ct screenin...
20123848 - Progress and applications of mouse models for human lung cancer.
22652808 - Expression pattern and targeting of her family members and igf-ir in pancreatic cancer.
20073558 - Inhalation adjuvant therapy for lung cancer.
22903548 - Diagnostic and prognostic significance of serum micrornas in colorectal cancer.
21644918 - Anticancer properties of flavonoids: roles in various stages of carcinogenesis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice     Volume:  4     ISSN:  1175-2203     ISO Abbreviation:  Am J Pharmacogenomics     Publication Date:  2004  
Date Detail:
Created Date:  2004-06-03     Completed Date:  2004-09-16     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  100967746     Medline TA:  Am J Pharmacogenomics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  169-76     Citation Subset:  IM    
Affiliation:
Preclinical Development-Oncology, CuraGen Corporation, Branford, Connecticut 06405, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy,  epidemiology,  genetics,  pathology
Disease Progression
Genome
Humans
Lung Neoplasms / drug therapy,  epidemiology,  genetics*,  pathology*
Neoplasm Proteins / biosynthesis,  genetics
Oligonucleotide Array Sequence Analysis
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Neoplasm Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment ...
Next Document:  Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers.